- Anthony P. Adamis, MD
- Vice President, Global Head of Ophthalmology - Genentech
Adjunct Professor of Ophthalmology & Visual Science - University of Illinois
Lecturer, Department of Ophthalmology - Harvard Medical School
- Anthony P. Adamis, M.D. was co-founder and CEO of Jerini Ophthalmic until the company was acquired by Shire in 2009. Prior to that, Dr. Adamis was a co-founder of Eyetech Pharmaceuticals and served as its Chief Scientific Officer until its acquisition by OSI Pharmaceuticals. Eyetech developed and obtained FDA and EMEA approval for the first anti-VEGF drug in ophthalmology. From 1992 to 2002, Dr. Adamis served on the full-time faculty of the Harvard Medical School. He was an NIH-supported principal investigator and co-director of the Retina Research Institute for Diabetic Retinopathy and Macular Degeneration at the Massachusetts Eye and Ear Infirmary. Dr. Adamis co-discovered the role that VEGF plays in new blood vessel growth and blood vessel leakage related to various diseases of the eye. He also co-discovered the role that PDGF-B plays in the regression of ophthalmic vessels, and the causal role of inflammation in the pathogenesis of diabetic retinopathy. Dr. Adamis received his M.D. with Honors from the University of Chicago and completed his ophthalmology residency at the University of Michigan. His research training in vascular biology was with Dr. Judah Folkman at the Children’s Hospital of Boston.
<< Go Back